STAT April 15, 2024
Ed Silverman

Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and refreshing, because that oh-so familiar routine of phone calls, online meetings, and rushing about has predictably returned. But what can you do? The world, such as it is, continues to spin. So time to give it a nudge in a better direction with a cup or three of stimulation. Our choice today is buttery pecan. A delightful treat. Please feel free to join us. Meanwhile, here is the latest selection of items of interest, which we hope will prove educational. And so, onward. We hope you have a meaningful and productive day. And please do keep in touch. …

In response to controversy,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
STAT+: Doctors Without Borders challenges pharma by releasing costs for a key clinical trial
Oh, Canada: U.S. Patients Don't Want Your Health Policies
STAT+: House bill aimed at Chinese biotechs is advancing
STAT+: Pharmalittle: We’re reading about MorphoSys drug risks, an AstraZeneca admission, and more
Steep Ozempic, Wegovy prices face fresh scrutiny from officials

Share This Article